

AZUR PHARMA

March 15, 2006

**New Indication for FazaClo® (clozapine, USP) Orally Disintegrating Tablets:
Reducing Suicide Risk in Schizophrenia or Schizoaffective Disorders**

Dear Health Care Professional:

Winter or summer, the risk of suicide is an ever-present danger for your patients suffering with schizophrenia or schizoaffective disorder. Now, there is new hope for these at-risk patients as they struggle to escape the potentially fatal grip of their chronic mental illnesses.

The enclosed new prescribing information for FazaClo Orally Disintegrating Tablets incorporates a major advance in therapy – suicide risk reduction -- and includes the following key statement:

**Reducing the Risk of Recurrent Suicidal Behavior in
Schizophrenia or Schizoaffective Disorders**

FazaClo® (clozapine, USP) is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.

This new indication is based on proven superiority to olanzapine in an international, randomized clinical trial of almost 1000 patients. In this study, after two years of continued therapy comparing clozapine versus olanzapine, clozapine patients experienced 25% fewer suicide attempts or hospitalizations to prevent suicide. The majority of patients received the full range of supportive interventions, both behavioral and pharmacological, including antidepressants. Clozapine-treated patients required fewer ($p < .05$) concomitant psychotropic medications¹. These findings are associated with no other atypical antipsychotic molecule but clozapine.

¹ Meltzer HY, et al., Clozapine treatment for suicidality in schizophrenia: The International Suicide Prevention Trial. Archives of General Psychiatry, 2003, 60: 82-91. Study details may be found in the CLINICAL PHARMACOLOGY and INDICATIONS AND USAGE sections of the Prescribing Information for FazaClo.

Please consider FazaClo as you review your case load for the coming year. Consider whether all your at-risk suicidal patients with schizophrenia or schizoaffective disorder are receiving the unique life-saving potential of FazaClo.


Please note that when patients' lives are at risk, the new FazaClo prescribing information does not restrict use to treatment-resistant patients. For outpatients in particular, the convenience of FazaClo and the fact that 8 out of 10 patients reported liking FazaClo² should help promote adherence in this very vulnerable population.

Please see attached Full Prescribing Information including BOXED WARNINGS regarding agranulocytosis, seizures, myocarditis, other adverse cardiovascular and respiratory effects, and dementia-related psychosis in elderly patients. Phenylketonurics: FazaClo Orally Disintegrating Tablets contain phenylalanine.

If you have questions about FazaClo or this new suicide risk reduction indication, please contact your Azur Pharma Sales Specialist or Scientific Affairs Department at 877 FAZACLO (877-329-2256). Additional information and regular updates may be found at www.fazaclo.com.

Best wishes for the New Year.

Cordially,

A handwritten signature in black ink, appearing to read "Gilbert Honigfeld". The signature is written in a cursive style with a long horizontal line extending to the left.

Gilbert Honigfeld, Ph.D.
Vice-President for Scientific Affairs

Encl: FazaClo -- Full Prescribing Information

FazaClo[®] is a registered trademark of Azur Pharma, Inc.

² Data on file with US Food and Drug Administration: FazaClo approved New Drug Application (Alamo Pharmaceuticals)